Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure

Since the last decade, therapeutic options for the treatment of advanced renal cell carcinoma (RCC) increased considerably. The checkpoint-inhibitor therapy has emerged as a new treatment regimen with promising outcome [1 –3]. This is exemplified by inhibitors targeting the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) molecules [4] which have shown impressive improvements in treatment responses and patient survival [5,6]. Despite this success, response rates still remain only in the range of 20% [7], w hich emphasizes the need for increased knowledge on immunopathogenesis of RCC and on the role and phenotypical and functional characteristics of tumor-infiltrating lymphocytes (TIL).

Source: Urologic Oncology: Seminars and Original Investigations - July 30, 2018 Category: Urology & Nephrology Authors: Fiona Crossey, Stefanie Marx, Sebastian H ölters, Kai Schmitt, Rainer M. Bohle, Tina Schmidt, Michael Stöckle, Urban Sester, Martina Sester, Martin W.W. Janssen Source Type: research